COVID-19 drugs, vaccines and diagnostics that are developed and tested within new international guidelines can expect rapid assessment and authorisation.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
